- Report
- April 2024
- 80 Pages
Germany
From €1374EUR$1,500USD£1,170GBP
- Report
- April 2024
- 80 Pages
India
From €1374EUR$1,500USD£1,170GBP
- Report
- April 2024
- 80 Pages
Ireland
From €1374EUR$1,500USD£1,170GBP
- Report
- April 2024
- 80 Pages
Japan
From €1374EUR$1,500USD£1,170GBP
- Report
- April 2024
- 80 Pages
Poland
From €1374EUR$1,500USD£1,170GBP
- Report
- April 2024
- 80 Pages
United States
From €1374EUR$1,500USD£1,170GBP
- Report
- June 2023
- 87 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- May 2022
- 67 Pages
Global
From €1832EUR$2,000USD£1,559GBP
- Report
- November 2021
- 575 Pages
Global
From €3663EUR$4,000USD£3,119GBP
- Report
- September 2022
- 172 Pages
Global
From €2289EUR$2,499USD£1,949GBP
€3269EUR$3,570USD£2,784GBP
- Book
- November 2013
Global
The Alzheimer Disease Clinical Trial market is a subset of the larger Alzheimer's Disease Drugs market. It is composed of clinical trials conducted to evaluate the safety and efficacy of drugs for the treatment of Alzheimer's Disease. These trials are conducted by pharmaceutical companies, research institutions, and other organizations. The trials involve recruiting participants, administering the drug, and collecting data on the effects of the drug. The results of the trials are then used to determine whether the drug is safe and effective for treating Alzheimer's Disease.
The Alzheimer Disease Clinical Trial market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Biogen, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
